HEALTH OF WOMAN. 2019.3(139): 72–76; doi 10.15574/HW.2019.139.72

Kedrova A. G., Levakov S. A.
FSBI «Federal Scientific and Clinical Center for Specialized Types of Medical Aid and Medical Technologies of the Federal Medical-Biological Agency of Russia», Moscow, Russia
FSBOUPPG «Institute for Advanced Studies of the Federal Medical and Biological Agency of Russia», Moscow, Russia

Implementation of breast cancer screening using digital mammography improved the diagnosis of primary proliferative regressive structural changes in the breast, manifested as diffuse or diffusely-nodal deformations of tissues. Currently, women are significantly more likely to seek medical consultation for damages of the breast that could not be evaluated earlier. This requires the development of special tactics for their treatment andfollow-up. Nowadays, searching for prognostic markers and choosing adequate therapy for nodular and diffuse mastopathy are among the most discussed issues in mammology, because up to 25% of all breast cancer cases are diagnosed during the in situ phase. In this article we try to reassess the problem of dyshormonal changes in the breast and develop an optimal approach to their treatment.

Key words: diffuse dyshormonal breast dysplasia, Mastodynon^®, mastalgia, premenstrual syndrome, Vitex agnus-castus

REFERENCES

1. Seidlova-Wuttke D, Wuttke W. 2017. The pre­menstrual syndrome, premenstrual masto- dynia, fibrocystic mastopathy and infertil­ity have often common roots: effects of extracts of chasteberry (Vitex agnus-castus) as a solution. Clinical Phytoscience 3:6. https://doi.org/10.1186/s40816-016-0038-z.

2. Halbreich U, Ben-David M, Assael M, Bornstein R. 1976. Serum-prolatic in women with premenstrual syndrome. Lancet 2(7987):654—6. PMID: 60517. https://doi.org/10.1016/S0140-6736(76)92465-X

3. Gumenyuk EG. 2010. Some problems of pre­menstrual syndrome and alternative thera­py. Journal of obstetrics and gynecological diseases 2:38-45.

4. Silbernagl S, Lang F. 2016. Clinical pathophy­siology. Atlas. Prakticheskaya meditsina: 282-284. Moscow.

5. Kulagina NV. 2016. Treatment of diffuse dyshormonal breast dysplasia in women at menopausal transi­tion. Akusherstvo i ginekologiya. Obstetrics and Gynecology 11:136-42. https://doi.org/10.18565/aig.2016.11.136-142

6. Vysotskaya IV, Letyagin VP. 2017. Pharmacological effects and molecular mechanisms of action of a her­bal medicine containing Vitex agnus-cas­tus. Opukholi zhenskoy reproduktivnoy sistemy. Tumors of Female Reproductive System 1:14-9. https://doi.org/10.17650/1994-4098-2017-13-1-14-19

7. Williams AC. 1999. Measures of function and psychology. In: Textbook of Pain. Eds.:P.D. Wall, R. Melzack. New York: Churchill Livingstone: 427-446.

8. Del Pozo E, Wyss H, Tollis G et al. 1979. Pro­lactin and deficient luteal function. Obstet Gynecol 53(3):282-6. PMID: 424097.

9. Damiano JS, Wasserman E. 2013. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin Cancer Res 19(7):1644-50. https://doi.org/10.1158/1078-0432.CCR-12-0138; PMid:23515410.

10. Schulz KD, Del Pozo E, Lose KH et al. 1975. Successful treatment of mastodynia with the prolactin inhibitor bromocryptine (CB 154). Arch Gynеkol 220(1):83-7. https://doi.org/10.1007/BF00673151; PMid:1243527.

11. Burton A, Maskarinec G, Perez-Gomez B et al. 2017. Mammographic density and ageing: а collaborative pooled analysis of cross­sectional data from 22 countries world­wide. PLoS Med 14(6):e1002335. https://doi.org/10.1371/journal.pmed.1002335; PMid:28666001 PMCid:PMC5493289.

12. Murta EF, de Freitas MM, Velludo MA. 1992. Histologic changes in fibrocystic breast disease before and after treatment with bromocriptine. Rev Paul Med 110(6):251—6. PMID: 1341021.

13. Milewicz A, Gejdel E, Sworen H et al. 1993. Vitex agnus-castus extract in the treatment of luteal phase defects due to latent hyper­prolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung 43(7):752—6. PMID: 8369008.

14. Turner S, Mills S. 1993. A double-blind clinical trial on a herbal remedy for premenstrual syndrome; a case study. Сomplementary therapies in medicine 1(2):73—7. https://doi.org/10.1016/0965-2299(93)90096-V.

15. Lauritzen CH, Reuter HD, Repges R et al. 1997. Treatment of premenstrual tension syndrome with Vitex agnus-castus: con­trolled, double-blind study versus pyrido- xine. Phytomedicine 4(3):183—9. https://doi.org/10.1016/S0944-7113(97)80066-9.

16. Wuttke W, Splitt G, Gorkow C, Sieder C. 1997. Treatment of cyclical mastalgia: Results of a randomized, placebo-controlled, dou­ble-blind study. Geburtshilfe Frauenheilkd 57: 569-74. https://doi.org/10.1055/s-2007-1023139

17. Halaška M, Rauš К, Bĕles P et al. 1998. Treat­ment of cyclical mastodynia using an ex­tract of Vitex agnus-castus: results of a double-blind comparison with a pla­cebo. Ceska Gynekol 63(5):388-92. PMID: 9818496.

18. Ma L, Lin S, Chen R, Wang X. 2010. Treat­ment of moderate to severe premenstrual syndrome with Vitex agnus-castus (BNO 1095) in Chinese women. Gynec Endocrinol 26(8):612-6. https://doi.org/10.3109/09513591003632126; PMid:20334585.

19. Kilicdag EB, Tarim E, Bagis T et al. 2004. Fructus Vitex agnus-castus and bromocrip­tine for treatment of hyperprolactinemia and mastalgia. Int J Gyn Obs 85(3):292-3. https://doi.org/10.1016/j.ijgo.2004.01.001; PMid:15145274

20. Pakgohar M, Moradi M, Jamshidi AH, Mehran A. 2009. Assessment of Vitex agnus-cas­tus L. extract effect on treatment of pre­menstrual syndrome. J Med Plants 8(32):98-107, 185.

21. Ciotta L, Pagano I, Stracquadanio M et al. 2011. Psychic aspects of the premenstrual dysphoric disorders. New therapeutic strategies: our experience with Vitex agnus-castus. Minerva Ginecol 63(3):237–45. PMID: 21654609.

22. Zamani M, Neghab N, Torabian S. 2012. Therapeutic effect of Vitex agnus-castus in patients with premenstrual syndrome. Acta Med Iran 50(2):101–6. PMID: 22359078.

23. Burton A, Maskarinec G, Perez-Gomez B et al. 2017. Mammographic density and ageing: а collaborative pooled analysis of cross­sectional data from 22 countries world­wide. PLoS Med 14(6): e1002335. https://doi.org/10.1371/journal.pmed.1002335; PMid:28666001 PMCid:PMC5493289.